Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (41-50 of 117) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|March 13, 2024
Intraventricular CARv3-TEAM-E T Cells in Recurrent GlioblastomaBryan D Choi, Elizabeth R Gerstner, Matthew J Frigault, et al.
Leukemia|December 19, 2025
Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-TJoshua N Gustine, John A Scaringi, Fabian Bauer, et al.
Blood|May 28, 2020
Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?Matthew J Frigault, Sarah Nikiforow, Michael K Mansour, et al.
Blood Cancer Journal|November 1, 2022
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myelomaKevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, et al.
Transplantation and Cellular Therapy|February 15, 2026
Incidence of and Risk Factors for Delayed Engraftment after Post-Transplant CyclophosphamideLauren Scarpetti, Daniel E Schwartz, Weixing Huang, et al.
Blood|April 21, 2021
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphomaJonathan A Trujillo, James Godfrey, Yifei Hu, et al.
Blood Advances|June 25, 2025
Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapyJessica S Little, Angelica Medina Pena, E Bridget Kim, et al.
Journal for Immunotherapy of Cancer|May 9, 2024
Stealth transgenes enable CAR-T cells to evade host immune responsesKorneel Grauwet, Trisha Berger, Michael C Kann, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 25, 2020
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell LymphomaShruti Gupta, Harish Seethapathy, Ian A Strohbehn, et al.
Bone Marrow Transplantation|October 11, 2023
Low incidence of engraftment syndrome following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamideDaniel J Ikeda, Zachariah DeFilipp, Kerry Collier, et al.
Pageof 12

Showing results (41-50 of 117) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|March 13, 2024
Intraventricular CARv3-TEAM-E T Cells in Recurrent GlioblastomaBryan D Choi, Elizabeth R Gerstner, Matthew J Frigault, et al.
Leukemia|December 19, 2025
Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-TJoshua N Gustine, John A Scaringi, Fabian Bauer, et al.
Blood|May 28, 2020
Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?Matthew J Frigault, Sarah Nikiforow, Michael K Mansour, et al.
Blood Cancer Journal|November 1, 2022
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myelomaKevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, et al.
Transplantation and Cellular Therapy|February 15, 2026
Incidence of and Risk Factors for Delayed Engraftment after Post-Transplant CyclophosphamideLauren Scarpetti, Daniel E Schwartz, Weixing Huang, et al.
Blood|April 21, 2021
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphomaJonathan A Trujillo, James Godfrey, Yifei Hu, et al.
Blood Advances|June 25, 2025
Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapyJessica S Little, Angelica Medina Pena, E Bridget Kim, et al.
Journal for Immunotherapy of Cancer|May 9, 2024
Stealth transgenes enable CAR-T cells to evade host immune responsesKorneel Grauwet, Trisha Berger, Michael C Kann, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 25, 2020
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell LymphomaShruti Gupta, Harish Seethapathy, Ian A Strohbehn, et al.
Bone Marrow Transplantation|October 11, 2023
Low incidence of engraftment syndrome following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamideDaniel J Ikeda, Zachariah DeFilipp, Kerry Collier, et al.
Pageof 12